Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus

208Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent conformation. In X-linked nephrogenic diabetes insipidus, most of the mutant vasopressin 2 (V2) receptors are trapped in the endoplasmic reticulum and degraded. They are unable to reach the plasma membrane and promote water reabsorption through the principal cells of the collecting ducts. Herein is reported two types of experiments: In vivo studies to assess clinically a short-term treatment with a nonpeptide V1a receptor antagonist (SR49059) and in vitro studies in cultured cell systems. In patients, SR49059 decreased 24- h urine volume (11.9 ± 2.3 to 8.2 ± 2.0 L; P = 0.005) and water intake (10.7 ± 1.9 to 7.2 ± 1.6 L; P < 0.05). Maximum increase in urine osmolality was observed on day 3 (98 ± 22 to 170 ± 52 mOsm/kg; P = 0.05). Sodium, potassium, and creatinine excretions and plasma sodium were constant throughout the study. In vitro studies indicate that the nonpeptide V1a receptor antagonist SR49059 and the V1a/V2 receptor antagonist YM087 (Conivaptan) rescued cell surface expression and function of mutant V2 receptors. Mutant V2 receptors with nonsense mutations were not affected by the treatment. Misfolded V2 receptor mutants were rescued in vitro and also in vivo by nonpeptide antagonists. This therapeutic approach could be applied to the treatment of several hereditary diseases that result from errors in protein folding and kinesis. Copyright © 2006 by the American Society of Nephrology.

References Powered by Scopus

Conformational disease

840Citations
N/AReaders
Get full text

Therapeutic approaches to protein-misfolding diseases

755Citations
N/AReaders
Get full text

Accelerated transport and maturation of lysosomal α-galactosidase A in fabry lymphoblasts by an enzyme inhibitor

610Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology

437Citations
N/AReaders
Get full text

Vasopressin V1a and V1b receptors: From molecules to physiological systems

318Citations
N/AReaders
Get full text

Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus

245Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bernier, V., Morello, J. P., Zarruk, A., Debrand, N., Salahpour, A., Lonergan, M., … Bichet, D. G. (2006). Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. Journal of the American Society of Nephrology, 17(1), 232–243. https://doi.org/10.1681/ASN.2005080854

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 28

61%

Professor / Associate Prof. 10

22%

Researcher 6

13%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 16

33%

Biochemistry, Genetics and Molecular Bi... 15

31%

Medicine and Dentistry 12

25%

Pharmacology, Toxicology and Pharmaceut... 5

10%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 30

Save time finding and organizing research with Mendeley

Sign up for free